Table 1 Patient characteristics including treatment and pathological parameters
From: Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases
| BoM/ nBM (N) | BM (N) | |
|---|---|---|
| patients | 40 | 40 |
| deceased | 14 | 14 |
| Taxane (#) | 30 | 38 |
| DTX | 9 | 15 |
| Paclitaxel | 17 | 14 |
| both | 4 | 9 |
| mean follow-up (##) | ||
| days | 2492.95 | 2545.15 |
| years | 6.83 | 6.97 |
| age primary diagnosis (##) years | 55.6 | 52.4 |
| neoadjuvant therapy (#) | ||
| yes | 7 | 4 |
| no | 29 | 29 |
| u | 4 | 7 |
| T (#) | ||
| T1 | 9 | 7 |
| T2 | 15 | 13 |
| T3 | 5 | 7 |
| T4 | 6 | 7 |
| Tx | 1 | 1 |
| Tis | 0 | 1 |
| u | 4 | 4 |
| N (#) | ||
| N0 | 10 | 16 |
| N1 | 13 | 11 |
| N2 | 5 | 4 |
| N3 | 8 | 5 |
| u | 4 | 4 |
| M (#) | ||
| M0 | 17 | 23 |
| M1 | 15 | 8 |
| Mx | 1 | 1 |
| u | 7 | 8 |
| grading (#) * | ||
| G1 | 4 | 0 |
| G2 | 14 | 16 |
| G3 | 9 | 17 |
| u | 13 | 7 |
| ER (#) *** | ||
| + | 33 | 17 |
| - | 5 | 19 |
| u | 2 | 4 |
| PR (#) * | ||
| + | 26 | 15 |
| - | 12 | 20 |
| u | 2 | 5 |
| HER2/neu (#) * | ||
| + | 13 | 12 |
| - | 24 | 21 |
| u | 3 | 7 |
| triple negative (#) * | ||
| yes | 3 | 9 |
| no | 34 | 27 |
| u | 3 | 4 |
| intrinsic subtype (#) *** | ||
| luminal | 34 | 19 |
| basal-like | 3 | 9 |
| Erb-B2 overexpression | 0 | 8 |
| u | 3 | 4 |